Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).

You may also be interested in...

Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds

Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.

NME "Approvables" Outnumber Approvals Six To Two In October

An "approvable" action was three times more likely than approval for the new molecular entities with user fee goals in October, according to an analysis by Pharmaceutical Approvals Monthly.

Market Analysis From Decision Resources

Urinary Incontinence





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts